 | • レポートコード：MRC2-11QY04002 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は糖尿病用非インスリン療法のグローバル市場について調査・分析したレポートです。種類別（アルファ-グルコシダーゼ阻害剤、アミリンアゴニスト、ビグアニド、ジペプチジルペプチダーゼ-4（DPP4）阻害剤、グリニド/メグリチニド、GLP-1アナログ/ GLP-1アゴニスト、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、スルホニル尿素、チアゾリジンジオン）市場規模、用途別（モニタリング、診断、治療、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別糖尿病用非インスリン療法の競争状況、市場シェア ・世界の糖尿病用非インスリン療法市場：種類別市場規模 2015年-2020年（アルファ-グルコシダーゼ阻害剤、アミリンアゴニスト、ビグアニド、ジペプチジルペプチダーゼ-4（DPP4）阻害剤、グリニド/メグリチニド、GLP-1アナログ/ GLP-1アゴニスト、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、スルホニル尿素、チアゾリジンジオン） ・世界の糖尿病用非インスリン療法市場：種類別市場規模予測 2021年-2026年（アルファ-グルコシダーゼ阻害剤、アミリンアゴニスト、ビグアニド、ジペプチジルペプチダーゼ-4（DPP4）阻害剤、グリニド/メグリチニド、GLP-1アナログ/ GLP-1アゴニスト、ナトリウム-グルコース共輸送体2（SGLT2）阻害剤、スルホニル尿素、チアゾリジンジオン） ・世界の糖尿病用非インスリン療法市場：用途別市場規模 2015年-2020年（モニタリング、診断、治療、その他） ・世界の糖尿病用非インスリン療法市場：用途別市場規模予測 2021年-2026年（モニタリング、診断、治療、その他） ・北米の糖尿病用非インスリン療法市場分析：米国、カナダ ・ヨーロッパの糖尿病用非インスリン療法市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの糖尿病用非インスリン療法市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の糖尿病用非インスリン療法市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの糖尿病用非インスリン療法市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GSK、Eli Lilly、Sumitomo Dainippon Pharma、Intarcia Therapeutics、Servier、Pfizer、Merck、Dong-A Pharmaceutical、Luye Pharma Group、Eurofarma、Geropharm、Alkem Labs、SatRx、Jiangsu Hansoh Pharmaceutical、Novo Nordisk、Emisphere、Uni-Bio Science Group、Takeda、3SBio、Jiangsu Hengrui Medicine ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Non-Insulin Therapies for Diabetes Market
The global Non-Insulin Therapies for Diabetes market size is projected to reach US$ 32930 million by 2026, from US$ 30040 million in 2020, at a CAGR of 8.9%% during 2021-2026.
Global Non-Insulin Therapies for Diabetes Scope and Market Size
Non-Insulin Therapies for Diabetes market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-Insulin Therapies for Diabetes market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Market segment by Type, the product can be split into
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Market segment by Application, split into
Monitoring
Diagnosis
Treatment
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
1.4 Market by Type
1.4.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Alpha-glucosidase Inhibitors
1.4.3 Amylin Agonists
1.4.4 Biguanides
1.4.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
1.4.6 Glinides / Meglitinides
1.4.7 GLP-1 Analogs / GLP-1 Agonists
1.4.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
1.4.9 Sulfonylureas
1.4.10 Thiazolidinediones
1.4.11 Others
1.5 Market by Application
1.5.1 Global Non-Insulin Therapies for Diabetes Market Share by Application: 2020 VS 2026
1.5.2 Monitoring
1.5.3 Diagnosis
1.5.4 Treatment
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2015-2026)
2.2 Global Non-Insulin Therapies for Diabetes Growth Trends by Regions
2.2.1 Non-Insulin Therapies for Diabetes Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Insulin Therapies for Diabetes Historic Market Share by Regions (2015-2020)
2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Insulin Therapies for Diabetes Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Insulin Therapies for Diabetes Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Non-Insulin Therapies for Diabetes Players by Market Size
3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2015-2020)
3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
3.2.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2019
3.3 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
3.4 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
3.5 Date of Enter into Non-Insulin Therapies for Diabetes Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2015-2020)
4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2015-2020)
6.2 Non-Insulin Therapies for Diabetes Key Players in North America (2019-2020)
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
7 Europe
7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2015-2020)
7.2 Non-Insulin Therapies for Diabetes Key Players in Europe (2019-2020)
7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
8 China
8.1 China Non-Insulin Therapies for Diabetes Market Size (2015-2020)
8.2 Non-Insulin Therapies for Diabetes Key Players in China (2019-2020)
8.3 China Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
8.4 China Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
9 Japan
9.1 Japan Non-Insulin Therapies for Diabetes Market Size (2015-2020)
9.2 Non-Insulin Therapies for Diabetes Key Players in Japan (2019-2020)
9.3 Japan Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
9.4 Japan Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Non-Insulin Therapies for Diabetes Market Size (2015-2020)
10.2 Non-Insulin Therapies for Diabetes Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
11 India
11.1 India Non-Insulin Therapies for Diabetes Market Size (2015-2020)
11.2 Non-Insulin Therapies for Diabetes Key Players in India (2019-2020)
11.3 India Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
11.4 India Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Non-Insulin Therapies for Diabetes Market Size (2015-2020)
12.2 Non-Insulin Therapies for Diabetes Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
12.4 Central & South America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 GSK
13.1.1 GSK Company Details
13.1.2 GSK Business Overview
13.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
13.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020))
13.1.5 GSK Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
13.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 Sumitomo Dainippon Pharma
13.3.1 Sumitomo Dainippon Pharma Company Details
13.3.2 Sumitomo Dainippon Pharma Business Overview
13.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
13.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.3.5 Sumitomo Dainippon Pharma Recent Development
13.4 Intarcia Therapeutics
13.4.1 Intarcia Therapeutics Company Details
13.4.2 Intarcia Therapeutics Business Overview
13.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
13.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.4.5 Intarcia Therapeutics Recent Development
13.5 Servier
13.5.1 Servier Company Details
13.5.2 Servier Business Overview
13.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
13.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.5.5 Servier Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
13.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
13.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Dong-A Pharmaceutical
13.8.1 Dong-A Pharmaceutical Company Details
13.8.2 Dong-A Pharmaceutical Business Overview
13.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
13.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.8.5 Dong-A Pharmaceutical Recent Development
13.9 Luye Pharma Group
13.9.1 Luye Pharma Group Company Details
13.9.2 Luye Pharma Group Business Overview
13.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
13.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.9.5 Luye Pharma Group Recent Development
13.10 Eurofarma
13.10.1 Eurofarma Company Details
13.10.2 Eurofarma Business Overview
13.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
13.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
13.10.5 Eurofarma Recent Development
13.11 Geropharm
10.11.1 Geropharm Company Details
10.11.2 Geropharm Business Overview
10.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
10.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.11.5 Geropharm Recent Development
13.12 Alkem Labs
10.12.1 Alkem Labs Company Details
10.12.2 Alkem Labs Business Overview
10.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
10.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.12.5 Alkem Labs Recent Development
13.13 SatRx
10.13.1 SatRx Company Details
10.13.2 SatRx Business Overview
10.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
10.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.13.5 SatRx Recent Development
13.14 Jiangsu Hansoh Pharmaceutical
10.14.1 Jiangsu Hansoh Pharmaceutical Company Details
10.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
10.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
10.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.14.5 Jiangsu Hansoh Pharmaceutical Recent Development
13.15 Novo Nordisk
10.15.1 Novo Nordisk Company Details
10.15.2 Novo Nordisk Business Overview
10.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
10.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.15.5 Novo Nordisk Recent Development
13.16 Emisphere
10.16.1 Emisphere Company Details
10.16.2 Emisphere Business Overview
10.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
10.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.16.5 Emisphere Recent Development
13.17 Uni-Bio Science Group
10.17.1 Uni-Bio Science Group Company Details
10.17.2 Uni-Bio Science Group Business Overview
10.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
10.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.17.5 Uni-Bio Science Group Recent Development
13.18 Takeda
10.18.1 Takeda Company Details
10.18.2 Takeda Business Overview
10.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
10.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.18.5 Takeda Recent Development
13.19 3SBio
10.19.1 3SBio Company Details
10.19.2 3SBio Business Overview
10.19.3 3SBio Non-Insulin Therapies for Diabetes Introduction
10.19.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.19.5 3SBio Recent Development
13.20 Jiangsu Hengrui Medicine
10.20.1 Jiangsu Hengrui Medicine Company Details
10.20.2 Jiangsu Hengrui Medicine Business Overview
10.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
10.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
10.20.5 Jiangsu Hengrui Medicine Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Non-Insulin Therapies for Diabetes Key Market Segments
Table 2. Key Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
Table 3. Ranking of Global Top Non-Insulin Therapies for Diabetes Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Alpha-glucosidase Inhibitors
Table 6. Key Players of Amylin Agonists
Table 7. Key Players of Biguanides
Table 8. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Table 9. Key Players of Glinides / Meglitinides
Table 10. Key Players of GLP-1 Analogs / GLP-1 Agonists
Table 11. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Table 12. Key Players of Sulfonylureas
Table 13. Key Players of Thiazolidinediones
Table 14. Key Players of Others
Table 15. Global Non-Insulin Therapies for Diabetes Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Non-Insulin Therapies for Diabetes Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Non-Insulin Therapies for Diabetes Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2015-2020)
Table 19. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Non-Insulin Therapies for Diabetes Market Growth Strategy
Table 25. Main Points Interviewed from Key Non-Insulin Therapies for Diabetes Players
Table 26. Global Non-Insulin Therapies for Diabetes Revenue by Players (2015-2020) (Million US$)
Table 27. Global Non-Insulin Therapies for Diabetes Market Share by Players (2015-2020)
Table 28. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2019)
Table 29. Global Non-Insulin Therapies for Diabetes by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
Table 32. Date of Enter into Non-Insulin Therapies for Diabetes Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 35. Global Non-Insulin Therapies for Diabetes Market Size Share by Type (2015-2020)
Table 36. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2021-2026)
Table 37. Global Non-Insulin Therapies for Diabetes Market Size Share by Application (2015-2020)
Table 38. Global Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 39. Global Non-Insulin Therapies for Diabetes Market Size Share by Application (2021-2026)
Table 40. North America Key Players Non-Insulin Therapies for Diabetes Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Non-Insulin Therapies for Diabetes Market Share (2019-2020)
Table 42. North America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 43. North America Non-Insulin Therapies for Diabetes Market Share by Type (2015-2020)
Table 44. North America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 45. North America Non-Insulin Therapies for Diabetes Market Share by Application (2015-2020)
Table 46. Europe Key Players Non-Insulin Therapies for Diabetes Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Non-Insulin Therapies for Diabetes Market Share (2019-2020)
Table 48. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Non-Insulin Therapies for Diabetes Market Share by Type (2015-2020)
Table 50. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Non-Insulin Therapies for Diabetes Market Share by Application (2015-2020)
Table 52. China Key Players Non-Insulin Therapies for Diabetes Revenue (2019-2020) (Million US$)
Table 53. China Key Players Non-Insulin Therapies for Diabetes Market Share (2019-2020)
Table 54. China Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 55. China Non-Insulin Therapies for Diabetes Market Share by Type (2015-2020)
Table 56. China Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 57. China Non-Insulin Therapies for Diabetes Market Share by Application (2015-2020)
Table 58. Japan Key Players Non-Insulin Therapies for Diabetes Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Non-Insulin Therapies for Diabetes Market Share (2019-2020)
Table 60. Japan Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Non-Insulin Therapies for Diabetes Market Share by Type (2015-2020)
Table 62. Japan Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Non-Insulin Therapies for Diabetes Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Non-Insulin Therapies for Diabetes Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Non-Insulin Therapies for Diabetes Market Share (2019-2020)
Table 66. Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Non-Insulin Therapies for Diabetes Market Share by Type (2015-2020)
Table 68. Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Non-Insulin Therapies for Diabetes Market Share by Application (2015-2020)
Table 70. India Key Players Non-Insulin Therapies for Diabetes Revenue (2019-2020) (Million US$)
Table 71. India Key Players Non-Insulin Therapies for Diabetes Market Share (2019-2020)
Table 72. India Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 73. India Non-Insulin Therapies for Diabetes Market Share by Type (2015-2020)
Table 74. India Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 75. India Non-Insulin Therapies for Diabetes Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Non-Insulin Therapies for Diabetes Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Non-Insulin Therapies for Diabetes Market Share (2019-2020)
Table 78. Central & South America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Non-Insulin Therapies for Diabetes Market Share by Type (2015-2020)
Table 80. Central & South America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Non-Insulin Therapies for Diabetes Market Share by Application (2015-2020)
Table 82. GSK Company Details
Table 83. GSK Business Overview
Table 84. GSK Product
Table 85. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 86. GSK Recent Development
Table 87. Eli Lilly Company Details
Table 88. Eli Lilly Business Overview
Table 89. Eli Lilly Product
Table 90. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 91. Eli Lilly Recent Development
Table 92. Sumitomo Dainippon Pharma Company Details
Table 93. Sumitomo Dainippon Pharma Business Overview
Table 94. Sumitomo Dainippon Pharma Product
Table 95. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 96. Sumitomo Dainippon Pharma Recent Development
Table 97. Intarcia Therapeutics Company Details
Table 98. Intarcia Therapeutics Business Overview
Table 99. Intarcia Therapeutics Product
Table 100. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 101. Intarcia Therapeutics Recent Development
Table 102. Servier Company Details
Table 103. Servier Business Overview
Table 104. Servier Product
Table 105. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 106. Servier Recent Development
Table 107. Pfizer Company Details
Table 108. Pfizer Business Overview
Table 109. Pfizer Product
Table 110. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 111. Pfizer Recent Development
Table 112. Merck Company Details
Table 113. Merck Business Overview
Table 114. Merck Product
Table 115. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 116. Merck Recent Development
Table 117. Dong-A Pharmaceutical Business Overview
Table 118. Dong-A Pharmaceutical Product
Table 119. Dong-A Pharmaceutical Company Details
Table 120. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 121. Dong-A Pharmaceutical Recent Development
Table 122. Luye Pharma Group Company Details
Table 123. Luye Pharma Group Business Overview
Table 124. Luye Pharma Group Product
Table 125. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 126. Luye Pharma Group Recent Development
Table 127. Eurofarma Company Details
Table 128. Eurofarma Business Overview
Table 129. Eurofarma Product
Table 130. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 131. Eurofarma Recent Development
Table 132. Geropharm Company Details
Table 133. Geropharm Business Overview
Table 134. Geropharm Product
Table 135. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 136. Geropharm Recent Development
Table 137. Alkem Labs Company Details
Table 138. Alkem Labs Business Overview
Table 139. Alkem Labs Product
Table 140. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 141. Alkem Labs Recent Development
Table 142. SatRx Company Details
Table 143. SatRx Business Overview
Table 144. SatRx Product
Table 145. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 146. SatRx Recent Development
Table 147. Jiangsu Hansoh Pharmaceutical Company Details
Table 148. Jiangsu Hansoh Pharmaceutical Business Overview
Table 149. Jiangsu Hansoh Pharmaceutical Product
Table 150. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 151. Jiangsu Hansoh Pharmaceutical Recent Development
Table 152. Novo Nordisk Company Details
Table 153. Novo Nordisk Business Overview
Table 154. Novo Nordisk Product
Table 155. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 156. Novo Nordisk Recent Development
Table 157. Emisphere Company Details
Table 158. Emisphere Business Overview
Table 159. Emisphere Product
Table 160. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 161. Emisphere Recent Development
Table 162. Uni-Bio Science Group Company Details
Table 163. Uni-Bio Science Group Business Overview
Table 164. Uni-Bio Science Group Product
Table 165. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 166. Uni-Bio Science Group Recent Development
Table 167. Takeda Company Details
Table 168. Takeda Business Overview
Table 169. Takeda Product
Table 170. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 171. Takeda Recent Development
Table 172. 3SBio Company Details
Table 173. 3SBio Business Overview
Table 174. 3SBio Product
Table 175. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 176. 3SBio Recent Development
Table 177. Jiangsu Hengrui Medicine Company Details
Table 178. Jiangsu Hengrui Medicine Business Overview
Table 179. Jiangsu Hengrui Medicine Product
Table 180. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020) (Million US$)
Table 181. Jiangsu Hengrui Medicine Recent Development
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2020 VS 2026
Figure 2. Alpha-glucosidase Inhibitors Features
Figure 3. Amylin Agonists Features
Figure 4. Biguanides Features
Figure 5. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features
Figure 6. Glinides / Meglitinides Features
Figure 7. GLP-1 Analogs / GLP-1 Agonists Features
Figure 8. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features
Figure 9. Sulfonylureas Features
Figure 10. Thiazolidinediones Features
Figure 11. Others Features
Figure 12. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2020 VS 2026
Figure 13. Monitoring Case Studies
Figure 14. Diagnosis Case Studies
Figure 15. Treatment Case Studies
Figure 16. Others Case Studies
Figure 17. Non-Insulin Therapies for Diabetes Report Years Considered
Figure 18. Global Non-Insulin Therapies for Diabetes Market Size YoY Growth 2015-2026 (US$ Million)
Figure 19. Global Non-Insulin Therapies for Diabetes Market Share by Regions: 2020 VS 2026
Figure 20. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2021-2026)
Figure 21. Porter's Five Forces Analysis
Figure 22. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2019
Figure 23. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2019
Figure 24. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2019
Figure 25. North America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Europe Non-Insulin Therapies for Diabetes Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Central & South America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2015-2020) (Million US$)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed
αグルコシダーゼ阻害剤の世界市場（～2026年） Alpha-glucosidase is an enzyme that is inhibited by alpha-glucosidase inhibitor drugs. Alpha-glucosidase helps in absorption of carbohydrates by breaking down carbohydrates into tiny sugar molecules such as glucose. The inhibition is reversible, and competitive inhibition. Alpha-glucosidase inhibito…- ジペプチドペプチダーゼ4（DPP-4）阻害剤の世界市場（～2026年） Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce t…
- 糖尿病治療の世界市場（～2026年） Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system. As living standards improve, an increasing obesity, the Diabetes Treatment has improved people's living habits, disease control effect, is becoming m…
- 無針糖尿病治療の世界市場（～2026年） Diabetes is a metabolic disorder in this condition person will have high blood glucose levels than the normal blood glucose. This is mainly due to inadequate insulin production or body cells are unable to respond to the produced insulin in the body or both. Symptoms of Diabetes are hyperglycemic con…
- CISインスリンの世界市場（～2026年） Insulin is a peptide hormone produced by beta cells of the pancreatic islets, which is considered to be the main anabolic hormone of the body. Russia is estimated to witness a significant growth over the next decade owing to the various subsidies provided by the local government. Market Analysis and…